The Healthcare Study Examines the Humoral Anti-S1 Antibody Response Following mRNA Vaccination, Comparing Individuals with and without Prior SARS-CoV-2 Infection
By:
References
- Amanat F, Thapa M, Lei T et al (2021) SARS-CoV-2-mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2. Cell 184:3936–3948.
https://doi.org/10.1016/j.cell.2021.06.005 - Bettini E, Locci M (2021) SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines 9:147.
https://doi.org/10.3390/vaccines9020147 - Catanzaro M, Fagiani F, Racchi M et al (2020) Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 5:84.
https://doi.org/10.1038/s41392-020-0191-1 - Dan JM, Mateus J, Kato Y et al (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371:eabf4063.
https://doi.org/10.1126/science.abf4063 - Decru B, van Elslande J, Steel S et al (2022) IgG anti-spike antibodies and surrogate neutralizing antibody levels decline faster 3 to 10 months after BNT162b2 vaccination than after SARS-CoV-2 infection in healthcare workers. Front Immunol 13:909910.
https://doi.org/103389/fimmu.2022.909910 - Ebinger JE, Botwin GJ, Albert CM et al (2020) Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers. BMJ Open 11:e043584.
https://doi.org/10.1136bmjopen-2020-043584. - Ebinger JE, Fert-Bober J, Printsev I et al (2021) Antibody response to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 27:981–984.
https://doi.org/10.1038/s41591-021-01325-6 - Esmaelizadeh A, Elahi R (2020) Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol 236:2519–2543.
https://doi.org/10.1002/jcp.30076 - Falsey AR, Frenck RW, Walsh EE et al (2021) SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. Correspondence. N Engl J Med 385:1627–1629.
https://doi.org/10.1056/NEJMc2113468 - Fraley E, LeMaster C, Geanes E et al (2021) Humoral immune response during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Med 19:169.
https://doi.org/10.1186/s12916-021-02055-9 - Garcia-Beltran WF, Lam EC, Astudilo MG et al (2021) COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184:476–488.
https://doi.org/10.1016/j.cell.2020.12.015 - Goel RR, Apostolidis SA, Painter MM et al (2021) Distinct antibody and memory B-cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol 6:eabi6950.
https://doi.org/10.1126/sciimmunol.abi6950 - Kim N, Minn D, Park S et al (2021) Positivity of SARS-CoV-2 antibodies among Korean healthy healthcare workers 1 and 2 weeks after second dose of Pfizer-BioNTech vaccination. J Korean Med Sci 36:e158.
https://doi.org/10.3346/jkms.2021.36.e158 - Laidlaw BJ, Ellebedy AH (2022) The germinal center B-cell response to SARS-CoV-2. Nat Rev Immunol 22:7–18.
https://doi.org/10.1038/s41577-021-00657-1 - Maltezou HC, Dounias G, Rapisarda V et al (2022) Vaccination policies for healthcare personnel: current challenges and future perspective. Vaccine X 11:100172.
https://doi.org/10.1016/j.jvacx.2022.100172 - Melgoza-González EA, Hinojosa-Trujillo D, Reséndiz-Sandoval M et al (2022) Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. Transbound Emerg Dis 69:e734–e745.
https://doi.org/10.1111/tbed.14344 - Mortaz E, Tabars P, Varahram M et al (2020) The immune response and immunopathology of COVID-19. Front Immunol 11:2037.
https://doi.org/10.3389/fimmu.2020.02037 - Padoan A, Cosma CH, della Rocca F et al (2022) A cohort analysis of SARS-CoV-2 anti-spike protein receptor domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated health-care workers. Clin Chem Lab Med 60:1110–1115.
https://doi.org/10.1515/cclm-2022-0322 - Roltgen K, Nielsen SCA, Silva O et al (2022) Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185: 1025–1040.
https://doi.org/10.1016/j.cell.2022.01.018 - Saadat S, Tehrani ZH, Logue J et al (2021) Binding and neutralization antibodies titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 325: 1467–1469.
https://doi.org/10.1001/jama.2021.3341 - Salleh MZ, Norazmi MN, Deris ZZ (2022) Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. Peer J 10:e13083.
https://doi.org/10.7717/peerj.13083 - Sette A, Crotty S (2021) Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184:861–880.
https://doi.org/10.1016/j.cell.2021.01.007 - Staruszkiewicz M, Pituch-Noworolska A, Skayne M et al (2022) Induction of IgA antibodies against S1 protein of SARS-CoV-2 after mRNA vaccine. J Immunol Inflam Dis Ther 5(3).
https://doi.org/10.31579/2637-8876/043 - Sterlin D, Mathian A, Miyara M et al (2021) IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 13:eabd2223.
https://doi.org/10.1126/scitranslmed.abd2223 - Tregoning JS, Brown ES, Cheeseman HM et al (2020) Vaccines for COVID-19. Clin Exp Immunol 202:162–192.
https://doi.org/10.1111/cei.13517 - Vabret N, Britton GJ, Gruber C et al (2020) Immunology of COVID-19. Immunity 52:910–941.
https://doi.org/10.1016/j.immuni.2020.05.002 - Van Elslande J, Oyaert M, Lorent N et al (2022) Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn Microbiol Infect Dis 103:115659.
https://doi.org/10.1016/j.diagmicrobio.2022.115659 - Vaquero ST, de Campos-Mata L, Ramada JM et al (2021) The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without preexisting immunity. Front Immunol 12:737083.
https://doi.org/10.3389/fimmu.2021.737083 - Vashishtha VM, Kumar P (2021) Development of SARS-CoV-2 vaccines: challenges, risks and the way forward. Hum Vaccin Immunother 17:1635–1649.
https://doi.org/10.1080/21645515
DOI: https://doi.org/10.2478/aite-2024-0016 | Journal eISSN: 1661-4917
Language: English
Submitted on: Feb 27, 2024
Accepted on: Jun 5, 2024
Published on: Aug 15, 2024
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2024 Małgorzata Staruszkiewicz, Anna Pituch-Noworolska, Mohamad Skayne, Torsten Matthias, Szymon Skoczen, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.